Skip to main content
. 2018 Dec 12;38(50):10595–10606. doi: 10.1523/JNEUROSCI.1700-18.2018

Figure 4.

Figure 4.

PrPC is required for tau-mediated inhibition of LTP. A, Effect of pre-injection of the anti-PrP mAb 6D11 intracerebroventricularly on the ability of SτAs to inhibit LTP. Animals received intracerebroventricular injections of vehicle twice (Veh + Veh; black diamonds; n = 5), 6D11 mAb (20 μg) before P301S SτAs (6D11 + SτAs; gray circles; n = 5) or IgG2a isotype control antibody (20 μg) followed by P301S SτAs (IgG2a + SτAs; open squares; n = 5). B, Values at 3 h post-HFS from A. C, D, Intracerebroventricular injection of the anti-PrP mAb MI-0131 before administration of AD1 extract prevented the inhibition of LTP. Animals were pretreated with 20 μg MI-0131 (MI-0131 + AD1/46-4; open squares; n = 5) or the isotype control mAb Avastin (Avastin + AD1/46-4; gray circles; n = 5). D, Values at 3 h from C. E, Effect of pre-injection of the anti-PrP mAb MI-0131 on the ability of the Aβ-ID soluble AD3 brain extract to inhibit LTP. Animals were pretreated with 20 μg MI-0131 (MI-0131 + AD3/AW7; n = 5) or the isotype control mAb 6E10 (6E10 + AD3/AW7; n = 5). #p < 0.05, ##p < 0.01 (paired t test); ***p < 0.001 ****p < 0.0001 (RM-2W-ANOVA, Tukey or Bonferroni post hoc test as appropriate).